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Abstract
The number of individuals with age-related cognitive impairment is rising dramatically in the UK and globally. There is
considerable interest in the general hypothesis that improving the diet of older people may slow the progression of
cognitive decline. To date, there has been little attention given to the possible protective role of n-3 long-chain
polyunsaturated fatty acids (n-3 LCPs) most commonly found in oily fish, in age-related loss of cognitive function. The
main research hypothesis of this study is that an increased dietary intake of n-3 LCPs will have a positive effect on
cognitive performance in older people in the UK.
To test this hypothesis, a double-blind randomised placebo-controlled trial will be carried out among adults aged 70–79
years in which the intervention arm will receive daily capsules containing n-3 LCP (0.5 g/day docosahexaenoic acid and
0.2 g/day eicosapentaenoic acid) while the placebo arm will receive daily capsules containing olive oil. The main outcome
variable assessed at 24 months will be cognitive performance and a second major outcome variable will be retinal
function. Retinal function tests are included as the retina is a specifically differentiated neural tissue and therefore
represents an accessible window into the functioning of the brain.
The overall purpose of this public-health research is to help define a simple and effective dietary intervention aimed at
maintaining cognitive and retinal function in later life. This will be the first trial of its kind aiming to slow the decline of
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cognitive and retinal function in older people by increasing daily dietary intake of n-3 LCPs. The link between cognitive
ability, visual function and quality of life among older people suggests that this novel line of research may have
considerable public health importance.
Background and rationale
The number of individuals with age-related cognitive
impairment is rising dramatically in the UK [1] and glo-
bally [2]. Global burden of disease estimates now place
dementia above stroke, musculoskeletal disorders, cardio-
vascular disease and all forms of cancer in terms of the
percentage of years lived with disability in people aged 60
years and older [2]. Defining simple and effective strate-
gies to prevent or delay cognitive impairment among
older people is therefore a priority for healthcare and
social services.
There has been specific interest in the hypothesis that
enhancing the diet of older people may act to slow the
progression of cognitive decline. The importance of good
nutrition among older people for the maintenance of
health has long been advocated, and evidence-based die-
tary recommendations for older people have been pub-
lished [3]. However, for a variety of functional,
physiological, psychological and social reasons older peo-
ple are nutritionally vulnerable, and frequently consume
diets that are poor in both quality and quantity resulting
in macronutrient and micronutrient under-nutrition.
Interest has recently turned to the potential importance of
n-3 long-chain polyunsaturated fatty acids (n-3 LCPs),
largely obtained from oily fish, in the maintenance of
good cognitive health. The brain is particularly rich in the
n-3 LCP docosahexaenoic acid (DHA), and n-3 LCPs have
repeatedly been shown to be crucial to brain development
in humans [4]. Age-related decrease in n-3 LCP level in
total brain lipids have been reported in humans, and it
has been postulated that this decline is correlated in part
with age-related deterioration of functions of the central
nervous system [5,6]. This findings may be particularly
relevant in the UK since recent survey data [7] demon-
strates that older people in the UK habitually consume a
diet that is low in fish.
A recent cross-sectional survey has reported that higher
fatty fish and n-3 LCP consumption is associated with
reduced risk of cognitive impairment [8], and prospective
studies have demonstrated that increased fish consump-
tion is associated with decreased risk of dementia [9,10]
and Alzheimer's disease [11] among older people. Data
from a cohort study recently suggested that reported daily
use of fish-oil supplements was associated with improved
scores in cognitive function at age 64 years, even after cor-
recting for childhood cognitive ability [12].
Numerous randomised controlled trials have demon-
strated that a relative sufficiency of n-3 LCPs results in
improved sensitivity to light in infancy [4]. It is thought
that this results from the ability of n-3 LCPs (specifically
DHA) in rod outer segments of the retina, to enhance
photoreceptor signal transduction processing. Relative
inadequacy of DHA results in decreased signal transduc-
tion, and DHA deficient subjects therefore require greater
light stimulation to elicit the same level of photoelectric
response. In addition DHA plays a key role in photorecep-
tor growth and functional development, a role which has
recently been demonstrated to be mediated by DHA
effects on gene expression [13].
A highly significant change occurring in the ageing retina
is a decrease in phototransduction efficiency in rods
resulting in a decreased sensitivity of rods to light [14].
Part of this decreased sensitivity may be associated with
reduction in DHA levels, such as also occurs in the ageing
brain, and may be susceptible to dietary manipulation. It
is hypothesised that increasing dietary DHA intake among
older people will result in increased levels of DHA in the
brain and retina, and therefore enhance phototransduc-
tion efficiency and consequently light sensitivity.
A recent Cochrane review [15] concluded that there was a
growing body of evidence from biological, observational
and epidemiological studies that suggested a protective
effect of n-3 LCPs against dementia. However, the
Cochrane review team was unable to locate a single pub-
lished randomised controlled trial on which to base rec-
ommendations for the use of dietary or supplemental n-3
LCPs for the prevention of cognitive impairment or
dementia. The current study will be the first trial of its
kind aiming to slow the decline of cognitive and retinal
function in older people by increasing daily dietary intake
of n-3 LCPs. The link between cognitive ability, visual
function and quality of life among older people suggests
that this novel line of research may have considerable
public health importance. Furthermore, improving the
quality of life and independence of older people, may
help to reduce the number of disability-adjusted life-years
lost through poor cognitive and retinal function in the
UK.
Design and methodology
Design
The study is designed as a double-blind randomised pla-
cebo-controlled trial. The procedures are illustrated sche-
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matically in Figures 1 and 2, and detailed in the text. The
trial aims to test two primary hypotheses.
Study hypotheses
Cognitive function study – for healthy, cognitively nor-
mal adults aged 70–79 years of age, daily supplementa-
tion with n-3 LCPs (500 mg DHA and 200 mg EPA) will
slow the rate of cognitive decline.
Retinal function study – for healthy, cognitively normal
adults aged 70–79 years of age, daily supplementation
with n-3 LCPs (500 mg DHA and 200 mg EPA) will
improve visual function by enhancing rod photoreceptor
response to light and visual-cortical integration.
Inclusion criteria
(i) Centres
20 National Health Service general practices, members of
the Medical Research Council General Practice Research
Framework (GPRF) will be recruited. The retinal function
sub-study practices will be situated in the Southeast of
England to facilitate attendance at Moorfields Hospital.
(ii) Patients
Participating general practices, will draw a sample of
healthy, cognitively-normal adults aged 70–79 years from
their practice registers. These potential participants will be
pre-screened for eligibility, by study nurses employed by
each practice, using available clinic records and a GPRF
computer identifier programme. Individuals currently
diagnosed with either diabetes (Type I or Type II) or
dementia will be excluded. The exclusion of individuals
with diabetes is necessary as these individual will have
raised susceptibility to vascular and neural damage and
may therefore be less sensitive to the proposed interven-
tion. Individuals with pre-diagnosed dementia will be
excluded as the intervention is aimed at delaying cognitive
decline in people who are currently not demented. The list
of potential participants will be checked by the named
General Practitioner in the clinic who will use discretion
to exclude individuals not deemed suitable to take part in
the study (e.g. recent bereavement, terminal illness).
Eligible individuals identified by this process will each
receive a letter and information sheet from their general
practice outlining the nature and importance of the study.
The letter will also act as a screen for potential participants
Flow-chart of retinal function study protocoligure 2
Flow-chart of retinal function study protocol.
Select, inform and enrol  
participating general practices (n=20) 
Pre-screen potential participants aged 70-79 
years for diabetes and dementia using clinic 
records and computer identifier programme 
Exclude: individuals with 
diabetes or dementia 
Write to ~4500 pre-screened potential participants 
inviting them to attend general practice 
Exclude: daily fish oil 
supplement consumers 
Pre-intervention clinic attendance 
Screen for possible dementia (MMSE <24) 
Exclude: individuals 
with MMSE <24 
Request full informed consent for cognitive function testing 
 
 
Carry-out baseline cognitive function testing 
 
Screen for eye health 
Exclude: individuals 
with poor eye health 
Request full informed consent for retinal function testing 
Enrol and randomly allocate to  
intervention or control arm (n=28 each) 
Carry-out baseline retinal function testing 
Initiate dietary intervention 
Placebo Intervention 
7x3-monthly repeat visits 
to distribute supplements 
and monitor compliance 
Carry-out post-intervention retinal and 
cognitive function testing at 24 months 
P
ar
ti
ci
p
an
t 
se
le
ct
io
n
, 
p
re
-s
cr
ee
n
in
g
 a
n
d
 
b
as
el
in
e 
d
at
a 
co
ll
ec
ti
o
n
 (
6
 m
o
n
th
s)
 
In
te
rv
en
ti
o
n
 (
2
4
 m
o
n
th
s)
 
Flow-chart of cognitive function study protocoligure 1
Flow-chart of cognitive function study protocol.
Select, inform and enrol 
participating general practices (n=20) 
Pre-screen potential participants aged 70-79 
years for diabetes and dementia using clinic 
records and computer identifier programme 
Exclude: individuals with 
diabetes or dementia 
Write to ~4500 pre-screened potential participants 
inviting them to attend general practice 
Exclude: daily fish oil 
supplement consumers 
Pre-intervention clinic attendance 
Screen for possible dementia (MMSE <24) 
 
Exclude: individuals 
with MMSE <24 
Request full informed consent  
for cognitive function testing 
Enrol and randomly allocate to  
intervention or control arm (n=399 each) 
Carry-out baseline 
cognitive function testing 
Initiate dietary intervention 
Placebo Intervention 
7x3-monthly repeat visits 
to distribute supplements 
and monitor compliance 
Carry-out post-intervention 
cognitive function testing at 24 months 
 
P
ar
ti
ci
p
an
t 
se
le
ct
io
n
, 
p
re
-s
cr
ee
n
in
g
 a
n
d
 
b
as
el
in
e 
d
at
a 
co
ll
ec
ti
o
n
 (
6
 m
o
n
th
s)
 
In
te
rv
en
ti
o
n
 (
2
4
 m
o
n
th
s)
 
Nutrition Journal 2006, 5:20 http://www.nutritionj.com/content/5/1/20
Page 4 of 11
(page number not for citation purposes)
who are currently consuming fish-oil supplements. Partic-
ipants reporting the current daily use of fish-oil supple-
ments will be excluded from the trial. Potential
participants will be invited to make an appointment with
the research nurse at their local general practice. Partici-
pants will be offered the use of a taxi, or their travel costs
on public transport or mileage in private cars to attend the
appointment up to a maximum of £10. The invitation let-
ter will explicitly state that if they do not wish to take part
in the study, it will not prejudice the quality of health care
provision from their general practice.
On attending their general practice, potential participants
will be fully informed by the research nurse about the
nature and relevance of the trial, and exactly what will be
involved if they agree to take part. All potential partici-
pants will be told that a prerequisite of their joining the
study will be that they agree not to initiate non-study fish-
oil supplement use over the course of the trial. Potential
participants who remain interested in taking part in the
study, will then be asked to give consent to undergo a
short cognitive screen, the Mini Mental State Examination
(MMSE). The MMSE is an easy to administer test that has
been widely validated as a screen for dementia and will be
used to exclude participants with low cognitive status
[16]. Participants with an MMSE score of less than 24 (out
of a maximum of 30) will not be included in the trial, and
will be offered a referral to their General Practitioner for
further monitoring. The cut-off of less than 24 has tradi-
tionally been used as a marker for possible dementia in
adults. It is possible that individuals with an MMSE of 24
or greater may have mild dementia. However, given the
potential public health relevance of this trial, the purpose
of the proposed cut-off is to exclude individuals with pos-
sible frank dementia rather than select a highly function-
ing group of individuals. Individuals with an MMSE score
below 24 will be thanked for their time and co-operation.
Participants who score MMSE of 24 or greater will be
invited to give full, informed written consent to take part
in the main cognitive function study. Individuals unwill-
ing to participate further will be thanked for their time
and co-operation.
Individuals giving informed consent will be enrolled in
the trial. The research nurse will telephone the central ran-
domisation service to register the participant, giving iden-
tifying details and the participant's age. Randomisation
will allow secure blind allocation of eligible people to one
or other arm of the study. Following random allocation a
study number will be given for each study participant.
This will also be used to identify the supply of capsules to
be prescribed for each participant. The study number will
be entered on the participant's entry form. Pre-labelled
identical-looking packs of capsules (see Dietary Interven-
tion below) will be stored securely in the general practice.
Minimisation criteria will be used to ensure a balance of
key prognostic factors using the following two criteria: age
group (70–74 and 75–79 years) and general practice.
Participants will then be assessed by completing question-
naires and undertaking a series of tests (see Baseline Data
Collection below). The full set of baseline tests will take
approximately 60 minutes to complete. Any couples
recruited to the study will undertake their assessments
separately. Participants will be provided with the contact
details of the study nurses and trial manager. Information
will also be available from the trial web-site [17] for those
participants who wish to use this method of obtaining
information. Participants will be thanked for their time
and co-operation.
Cognitive function study
Outcome measures for cognitive function study
Primary outcome
Change in cognitive function at 24 months determined by
the California Verbal Learning Test. This is a test of mem-
ory of 16 words.
Secondary outcomes
Cognitive performance as measured by immediate and
delayed recall of a short story, tests of prospective mem-
ory, timed letter search/cancellation task, verbal fluency,
digit span forwards and backwards, symbol digit modali-
ties test, simple and choice reaction time, and spatial
memory.
Psychological health.
Compliance determined by counting the number of cap-
sules remaining every 3 months, and by measuring the
change in n-3 LCP concentration in buccal epithelial cells
over 24 months.
Blood pressure.
Change in Body Mass Index (a measure of body size).
Number of hospital admissions for cardiovascular events
over 24 months.
Death.
Sample size
The sample size required for this trial is based on a 0.3SD
difference between trial arms in long-delay free recall of
List A of the California Verbal Learning Test over the 24
months of intervention. To detect a 0.3SD difference
between trial arms, with 90% power and 1% significance,
332 individuals are required per treatment group. Allow-
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ing for 20% drop-out over 24 months of intervention, the
total sample size required for the study is 798 individuals.
A difference of 0.3SD is clinically relevant and would be
equivalent to individuals in the intervention arm being
able to remember one more word out of the 16 in the Cal-
ifornia Verbal Learning Test than those in the placebo arm
[18].
Recruitment
In order to attain this sample size it is expected that a sam-
ple of approximately 4500 individuals, pre-screened for
diabetes and dementia, will initially be drawn from the
registers of 20 participating general practices (around 225
patients aged 70–79 years per practice). A conservative
estimate of the proportion of eligible individuals who will
agree to participate in the trial is 20%. It is estimated that
it will take 6 months to enrol the full sample for this trial.
Baseline (pre-intervention) cognitive function data 
collection
At trial entry to enable randomisation
Initials
Date of birth
Gender
General practice number
MMSE score
Consent
Baseline data collection
1. Psychological health: the 30–item General Health
Questionnaire (GHQ-30) will be used to assess the affec-
tive state of participants [19]. The GHQ-30 is quick and
easy to administer, and an assessment of mood is impor-
tant as it may be associated with cognitive performance.
2. Educational achievement: the widely used Burnham
Scale of educational achievement will be used [20]. This is
an important covariate as educational level has been
shown to be strongly related to cognitive performance.
3. Blood pressure: this is necessary as hypertension is an
important consequence of the metabolic syndrome, and
individuals with high blood pressure may have a raised
susceptibility to vascular and neural damage. Baseline
blood pressure will therefore be used as a covariate in
analysis. Blood pressure will be measured using the auto-
mated DYNAMAP device. Two measurements each of
systolic and diastolic pressure will be taken in the sitting
position (the mean of the two measurements will be used
in analysis); participants will have rested for 5 minutes
before their blood pressure is measured and there will be
a minimum of 5 minutes between the two measurements.
Normal general practice procedures will be followed for
the management and treatment of high blood pressure.
4. Cardiovascular health: any history of hospital admis-
sion for myocardial infarction (MI) or stroke over the pre-
ceding 5 years will be abstracted from patient notes.
5. National Health Service number: So that the study
organisers do not lose contact with patients should they
move address and also to follow up on health status, par-
ticipants are being asked to give their agreement for their
names and NHS numbers to be sent to the NHS Central
Register.
6. Basic anthropometric measures: height and weight will
be measured using standardised procedures in order to
enable the calculation of the Body Mass Index: a basic
marker of body size.
7. Swab of cheek cells: nurses will collect a sample of buc-
cal mucosal epithelial cells from each participant. This is
a relatively non-invasive procedure in which a sterile
wooden spatula is scraped briskly along the inside of the
cheek (about 10 strokes on each cheek). The cheek cells
will be sent to laboratories, in sterile containers, to be ana-
lysed for their n-3 LCP concentration.
8. Fish consumption: two simple questions regarding
habitual fish consumption will be asked. Firstly, a ques-
tion regarding the frequency of fish consumption, and
second, participants will be asked to list the three species
of fish they consume most frequently.
9. Cognitive ability: the participants will be asked to com-
plete a validated series of cognitive tests. It is currently not
known which, if any, cognitive domain will be most
affected by n-3 LCP supplementation and therefore a
series of tests have been selected which cover the major
domains (memory, attention, psychomotor speed and
executive function):
a. Brief assessment of subjective symptoms of cognitive
impairment (memory, language/word-finding, concen-
tration).
b. Immediate and delayed recall of a short story (from the
Wechsler Memory Scale).
c. Immediate and delayed recall of a 16-item word list
(California Verbal Learning Test).
d. Three tests of prospective memory i.e. remembering to
carry out instructions without being reminded.
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e. Timed letter search/cancellation task (attention/psycho-
motor speed/executive function).
f. Verbal fluency – naming animals (word-finding/execu-
tive function).
g. Digit span forwards and backwards (working memory/
executive function) from the Wechsler Adult Intelligence
Scale.
h. Symbol digit modalities test (attention/psychomotor
speed/executive function).
i. Simple (psychomotor speed) and choice (decision
speed) reaction time.
j. Spatial memory (memory/visual spatial function).
Dietary intervention
Following the completion of the series of tests detailed
above, those participants not enrolled in the retinal func-
tion study will be introduced to the dietary intervention.
The dietary intervention will be a daily dietary supple-
ment in the form of capsules which will be identical in
size, shape, colour and smell for both the intervention
and placebo arms of the trial. Given the lack of trial evi-
dence to support the use of any particular level of dietary
supplementation, the dose selected in the OPAL study was
based on the following considerations: the UK Food
Standards Agency currently recommends that men and
post-reproductive age women consume one to four, 140 g
portions of oily fish a week [21]; typical dietary recom-
mendations, such as those of the World Health Organisa-
tion fall in the range 0.3–0.5 g n-3 LCPs daily [22]; the
dose of n-3 LCPs generally recognised as safe (GRAS) is 3
g per day.
Taking these considerations into account, a pragmatic
decision was made on the dose for the OPAL study. The
intervention arm will be asked to consume two 650 mg
soft-gel capsules daily containing a total of 500 mg DHA
and 200 mg EPA. This is equivalent to approximately 4.9
g of n-3 LCPs a week (0.7 g/day), a level that can be
achieved via the consumption of approximately 300 g
(slightly more than 2 portions) of fatty-fish a week. This
level of supplementation falls well below the upper GRAS
level and should thus be safe. The placebo arm will be
asked to consume two identical 650 mg capsules contain-
ing olive oil daily, this oil is rich in n-9 fatty acids and will
thus have a minimal effect on the 18:2 n-6/18:3 n-3 ratio.
Changes in the n-6/n-3 ratio may affect prostanoid bal-
ance which affects vascular and inflammatory responses.
The higher DHA to EPA ratio in the supplement is justi-
fied by the rationale of the study, which prioritises the
neuroprotective effect of DHA over the vascular and anti-
thrombotic effect of EPA.
The research nurses will explain the importance of con-
suming the capsules every day, suggesting that it should
become part of their daily routine, for example by always
consuming the capsules at breakfast-time. Participants
will be given a 3-month supply of capsules at the baseline
clinic visit, and asked to attend the clinic every 3-months
throughout the 24-month course of the trial i.e. at 3, 6, 9,
12, 15, 18 and 21 months. Participants will be sent
reminders to collect repeat supplies of capsules.
The participants enrolled in the retinal function study will
be introduced to the dietary intervention after their base-
line retinal function test (see below). These participants
will be invited back to the general practice after retinal
function testing to be given their dietary supplements.
Data collection at 3, 6, 9, 12, 15, 18, and 21 months
Participants will have appointments to meet the research
nurse every 3 months throughout the study (8 repeat visits
in total including 24 month assessment). During these
appointments, participants will be reminded of the
importance of the study and of the need to comply with
the study protocol. The research nurses will also record
any information the participants volunteer regarding any
discomfort caused by the capsules. The recognised side-
effects of n-3 LCP capsules include belching, flatulence,
abdominal discomfort and loose stools. These discom-
forts are generally mild and decrease over time, and the
research nurses will provide reassurance to any concerned
participants.
Participants will be asked to bring their dietary capsule
containers with them to the meeting so that any remain-
ing capsules can be counted as a measure of compliance.
Buccal cell swabs will also be taken during these repeat
appointments from a random 20% sample every 6
months (i.e. at 6, 12 and 18 months) as a further measure
of compliance. Participant records from the general prac-
tice will be consulted every 3 months in order to record
any hospital admissions for MI or stroke over the inter-
vening 3 month period.
Assessment at 24 months
A final evaluation of the cognitive function of all trial par-
ticipants will be carried out after 24 months of interven-
tion. Participants will be invited to attend their general
practice and will be assessed for:
1. Psychological health: as at baseline.
2. Blood pressure: as at baseline.
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3. Cardiovascular health: record of hospital admissions
for MI or stroke between the 21 and 24 month appoint-
ments.
4. Basic anthropometric measures: as at baseline.
5. Buccal cell DHA concentration: as at baseline. Collected
as a marker of the impact of the intervention on buccal
cell DHA concentration, and compliance in the interven-
tion arm of the trial.
6. Cognitive function: as at baseline.
Participants will be offered the use of a taxi, or their travel
costs on public transport or mileage in private cars to
attend the appointment up to a maximum of £10.
Data analysis for assessing change in cognitive function
Primary analysis will be carried out based upon the
groups as randomised ("intention to treat"). Results will
be presented as appropriate effects sizes with a measure of
precision (95% confidence intervals). Covariates such
age, gender, and baseline blood pressure and DHA con-
centration will be adjusted for in the analysis. Further
exploratory analyses will be based on those patients who
fully follow the treatment protocol.
Retinal function study
Outcome measures for retinal function study
Primary outcome
Change in rod sensitivity over 24 months of intervention
as measured by electroretinogram.
Secondary outcomes
Colour vision measured by detecting sensitivity to colour
contrast which is a good marker of central retinal func-
tion.
Eye health assessed by carrying out a full ophthalmic
examination.
Sample size
The calculation for the sample size required to demon-
strate a significant difference between the placebo and
intervention arms of the trial is based on the decline in
rod sensitivity with age [14]. In line with previous studies
on the effect of DHA during infant development, we antic-
ipate that an increase in dietary intake of DHA will signif-
icantly improve rod sensitivity; increases of the order of
+2SD in rod sensitivity have been demonstrated in studies
of DHA supplementation in preterm infants [23,24]. Con-
sidering the complexity of the study and the limited sig-
nificance of small changes in retinal sensitivity we have
defined a biologically significant effect as an increase of
1SD. To detect this effect with 90% power and 5% signif-
icance, the sample size required is 22 per group. Allowing
for 25% drop-out during the trial, the total sample size
required for this sub-study is 56 individuals.
Recruitment
Following the initial selection of 20 general practices to be
involved in the trial, 4–6 of these practices will be selected
to take part in the retinal function study. Potential partic-
ipants from these general practices will be informed about
the retinal function study as well as the cognitive function
study, and will be invited to take part in both studies.
During the initial meeting at the general practices, the
research nurses will fully outline the nature of the trial to
potential participants, and in addition, the nurses will
describe the objectives and methods of the retinal func-
tion tests. Potential participants who remain interested in
taking part in either the cognitive study or the cognitive
and retinal function study, will then be asked to give con-
sent to undergo a short cognitive screen, the MMSE (as
outlined above). Participants who have an MMSE score of
greater than or equal to 24 will be invited to give full,
informed consent to take part in the cognitive function
study. Individuals unwilling to participate further will be
thanked for their time and co-operation.
Sufficient information about participants giving informed
consent to take part in the cognitive function study will be
transmitted to the central randomisation service to allow
random allocation to one or other arm of the study. The
allocation will be minimised by age group (70–74 and
75–79 years) and centre. Participants will then undergo
the series of tests outlined above for the cognitive function
study (see Baseline cognitive function data collection).
After the collection of baseline cognitive function data
participants will be invited to consider the retinal function
study. Participants will be free to opt in or out of the reti-
nal function study. It will be explicitly stated that refusing
to take part in the retinal function study will not prejudice
the quality of treatment and support that they will receive
in the cognitive function study or from the general prac-
tice. Participants expressing an interest in taking part in
the retinal function study will be asked for consent to
carry-out a simple visual test (the Logmar test) and
respond to a few questions on eye health.
Any participant reporting a personal or family history of
genetically-determined ocular or neurological disease,
diabetes, glaucoma or age-related macular degeneration
will be excluded from the retinal function study. Partici-
pants on the retinal function study will also be required to
have a Logmar visual acuity of +0.2 or better. Participants
reporting poor eye-health or/and those with visual acuity
scores below +0.2 will be excluded from the retinal func-
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tion study (but not the trial in general) and offered a refer-
ral to their General Practitioner for further monitoring.
Participants with good eye-health and scoring +0.2 or bet-
ter on Logmar will be invited to give full, informed con-
sent to take part in the retinal function study. Following
the completion of the baseline cognitive function testing,
participants will be given an appointment at Moorfields
Eye Hospital for baseline retinal function testing. These
participants will not receive the dietary intervention until
they have completed their baseline retinal function tests.
Baseline (pre-intervention) retinal function data collection
1. Full electroretinogram (ERG): the ERG is a mass electri-
cal response of the retina to a luminance stimulus. It is
recorded through an electrode placed on the surface of the
eye, light stimuli are provided using a Ganzfeld dome
stimulator. The response typically consists of an "a-wave"
followed by a "b-wave". The first 10–12 milliseconds of
the a-wave arises in relation to photoreceptor hyperpolari-
sation, and the slope of the linear portion of the a-wave
can be related to the kinetics of phototransduction. The b-
wave is generated in the inner nuclear layer of the retina,
principally the ON-bipolar cells. Further recording will
examine the a-wave evoked by a brighter flash specifically
to examine the characteristics that can be related to pho-
totransduction.
2. Colour vision: trial participants will be tested for colour
vision which is a good measure of central retinal function.
This will be performed using a computerised system that
enables colour contrast sensitivity assessment by measur-
ing thresholds in the protan and tritan colour confusion
axes.
3. Ophthalmic examination: this will be conducted in
order to determine the "health" of the eye at baseline. Par-
ticipants will be fully informed of the health of their eyes.
In addition, fundus photography will be performed such
that if any changes in the ocular fundus occur that can be
putatively related to the dietary supplementation, docu-
mentary evidence will be available.
It is anticipated that the duration of the full protocol for
eye examination will be in the region of 2 hours. Although
these examinations may cause slight discomfort to some
participants, they are generally very well tolerated. ERG is
a standard ophthalmological investigation, and Moor-
fields Eye Hospital performs approximately 2000 ERGs
each year to standards in excess of those recommended by
the International Society for Clinical Electrophysiology of
Vision [25]. Participants will be offered the use of a taxi,
or their travel costs on public transport or mileage in pri-
vate cars to attend the baseline appointment at Moorfields
Eye Hospital up to a maximum of £20.
Dietary intervention
Following the completion of the cognitive function test
and the retinal function tests, trial participants will be
given an appointment to return to the general practice to
be introduced to the dietary intervention (see Dietary
intervention above).
Data collection at 3, 6, 9, 12, 15, 18, and 21 months
Participants involved in the retinal function study as well
as the cognitive function study will have appointments to
meet the research nurse every 3 months throughout the
study in an identical manner to those only involved in the
cognitive function study (see above).
Final (post-intervention) retinal function data collection
A final evaluation of the retinal function of trial partici-
pants will be carried out after 24 months of intervention.
Study participants included in the retinal function study
will be invited to attend Moorfields Eye Hospital where
they will be assessed as follows:
1. Full electroretinogram: as at baseline.
2. Colour vision: as at baseline.
3. Ophthalmic examination: as at baseline.
Participants will be fully informed of the results of their
eye examination, and offered the use of a taxi, or their
travel costs on public transport or mileage in private cars
to attend the 24 month appointment at Moorfields Eye
Hospital up to a maximum of £20.
Data analysis for assessing change in retinal function
Primary analysis will be carried out based upon the
groups as randomised ("intention to treat"). We will test
between group differences in change in rod sensitivity
over the 24-month follow-up. We will carry out secondary
outcome analysis on change in colour vision based on col-
our contrast specificity. Covariates such as age, gender,
and baseline blood pressure and DHA concentration will
be adjusted for in the analysis. Results will be presented as
appropriate effects sizes with a measure of precision (95%
confidence intervals). Further exploratory analyses will be
based on patients fully following the treatment protocol.
Trial organisation
Investigators
1. Alan Dangour (Principal Investigator PI): public health
nutritionist based at the London School of Hygiene &
Tropical Medicine (LSHTM). Will co-ordinate and man-
age the overall running of the trial and will be closely
involved in data analysis and paper writing.
Nutrition Journal 2006, 5:20 http://www.nutritionj.com/content/5/1/20
Page 9 of 11
(page number not for citation purposes)
2. Ricardo Uauy: senior public health nutritionist based at
LSTHM.
3. Astrid Fletcher: senior epidemiologist based at LSHTM.
4. Diana Elbourne: senior statistician based at LSHTM. Has
extensive RCT experience, will co-ordinate activity at the
LSHTM Data Coordinating Centre (DCC) with particular
responsibility for data management, entry and analysis.
5. Ann Truesdale: trial's advisor with expertise in protocol
development and co-ordination of RCTs based at LSHTM.
Will work closely with Diana Elbourne at the DCC and
will provide expertise on trial co-ordination and data
management.
6. Marcus Richards: senior neuropsychologist based at Uni-
versity College London.
7. Graham Holder: Director of Electrophysiology at Moor-
fields Eye Hospital.
8. Louise Letley: Senior Nurse Manager for the MRC GPRF
with six years experience of co-ordinating nurse managed
research projects in primary care. Has overall responsibil-
ity for the research nurses involved in the study and for the
management of quality control within the practices.
Trial Steering Committee
The overall scientific aspects of the project will be man-
aged by a Steering Committee. The Steering Committee
will include expert independent advisors Professor Sir
John Grimley Evans (Chair), Professor Martin Prince, Pro-
fessor Alan Bird, Dr. Madge Vickers (co-opted onto Steer-
ing Committee as independent member from January
2005), two members of the public Mrs. Ursula Shine and
Mrs. Yvonne Davidson, the principal applicants, and
project staff ex-officio. Members of the public are defined
here as: patients and potential patients; informal (unpaid)
carers; people who use health and social services; mem-
bers of the public who may be targeted by health promo-
tion programmes; organisations that represent the
interests of people who use health and social care services.
The Steering Committee will take all executive decisions.
The responsibility of the Steering Committee is to ensure
the scientific integrity and quality of the project. To
achieve this, the specific responsibilities of the Steering
Committee include:
- maintaining adherence to the study protocol
- approving changes to study protocol if required
- reviewing quality assurance indicators
- monitoring study recruitment and the overall study
timetable
- advising, as required, on specific scientific items that
may arise
- compliance with legislation
- adherence to research governance
- reporting to funders
- approving publication and dissemination strategies.
The Steering Committee will meet six monthly.
Project Management Group (PMG)
A Project Management Group (comprising principal
investigators, trial manager, senior nurse, database man-
ager and statistician) will run the trial on a day-to-day
basis to ensure the smooth operation of the project. Reg-
ular review meetings will be held with other members of
the team as appropriate.
The responsibilities of the PMG include:
- establishing and monitoring recruitment of participating
centres and participants
- distributing and supplying data collection forms and
other appropriate documentation for the trial
- distributing and supplying dietary supplements to trial
practices
- data collection and management
- data entry and cleaning
- data analysis
- organising and servicing the Data Management Commit-
tee
- organising and servicing the Trial Steering Committee.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will
be established. The membership will comprise Professor
Tom Sanders (Chair), Professor Graham Dunn (senior
statistician) and Dr. Gill Livingston (clinician). The role of
the DMC will be firstly to check on safety by random allo-
cation. Although this intervention is not expected to lead
to adverse consequences, it is important to guard against
this eventuality. If necessary, this could lead to stopping
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the trial before knowing the primary outcome. Secondly
the DMC will also look at on-going compliance data by
random allocation to check that a difference in exposure
is occurring. If a problem were to be detected, this could
lead to a recommendation to amend aspects of the proto-
col. Thirdly, the DMC will consider data at trial entry by
random allocation in order to be able to interpret the
compliance and side effects data. The committee will meet
at the start of the trial to agree terms of reference and then
at the end of the recruitment period and every 6 months
or as they determine.
Medical Research Council General Practice Research 
Framework (GPRF)
The responsibilities of the GPRF are to select and support
general practices from which the participants are to be
drawn. The GPRF will train, monitor and support research
nurses throughout the trial, assure recruitment and com-
pliance to the trial protocol, and collect high quality data
as detailed in the trial protocol. The trial manager, who
will liaise closely with the principal investigator, and
report to the GPRF senior clinical scientist, will be based
at the GPRF. In order to ensure that trial participants are
adequately supported and are able to adhere to the trial
regimen, the GPRF will also ensure the provision of direct
phone access to the trial manager who will liaise as neces-
sary to resolve possible problems that may affect compli-
ance and retention.
Data Coordinating Centre
The Data Co-ordinating Centre (DCC) will be based at the
LSHTM. The responsibilities of the DCC are to set-up and
run systems for data entry, data verification and the check-
ing of errors and overdue data reports in close liaison with
the GPRF, and to conduct interim and final analyses for
the cognitive and retinal function studies.
Moorfields Eye Hospital
The responsibilities of the investigator at Moorfields Eye
Hospital are to carry out retinal examinations at baseline
and 24-months of the sample agreeing to take part in the
retinal function study, co-ordinate with the GPRF and
DCC to ensure that participants attend as necessary, inter-
pret primary data and forward cleaned data to the DCC
for analysis.
Publication policy
To safeguard the scientific rigour of the trial, data from
this study will not be presented in public or submitted for
publication without requesting comments and receiving
agreement from the Trial Steering Committee. The pri-
mary results of the trial will be published with authorship
in relation to specific participation in the study, with the
name order to be presented by the PI for consideration by
the Trial Steering Committee. Suggested revisions in order
of authors should meet with the approval of the PI. Pub-
lications in specific areas of the study or on methodologi-
cal aspects can be led by co-investigators in their area of
expertise subject to approval by the Trial Steering Com-
mittee and the PI. The requirements for authorship will
follow recommended practice in journal guidelines.
Confidentiality
Participants will be identified by their trial number to
ensure confidentiality. However, as the participants in the
trial will be followed for 24 months following randomisa-
tion, it is essential that the teams at the GPRF have the
names and addresses of the trial participants recorded on
the data collection forms in addition to the allocated trial
number. Stringent precautions will be taken to ensure
confidentiality of names and addresses at the GPRF. The
investigators and local coordinators will ensure conserva-
tion of records in areas to which access is restricted.
Longer term follow-up
Further follow-up may be the subject of a separate proto-
col. So that the study organisers do not lose contact with
patients should they move address and also to follow up
on health status, participants are being asked to give their
agreement for their names and NHS numbers to be sent to
the NHS Central Register.
Conclusion
The number of individuals with age-related cognitive
impairment is rising worldwide, and public health inter-
ventions aimed at slowing this rise are urgently needed.
There is a growing body of mechanistic and epidemio-
logic evidence to support the proposal that n-3 LCPs may
reduce the risk of age-related loss of cognitive function in
older people. The current trial is designed to test the
hypothesis that an increased dietary intake of n-3 LCPs
will have a positive effect on cognitive performance in
older people in the UK. This will be the first trial of its
kind aiming to slow the decline of neuronal function in
older people by increasing daily dietary intake of n-3
LCPs. The link between cognitive ability and quality of life
among older people suggests that this novel line of
research may have considerable public health importance.
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